Telix Pharmaceuticals Limited announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix’s commercial PSMA-PET1 product, Illuccix® (68Ga-PSMA-11).
Subtle Medical’s SubtlePET™ is a U.S. Food and Drug Administration (FDA) cleared AI-driven solution to enhance the efficiency and effectiveness of imaging procedures. The proprietary deep-learning algorithm allows for faster PET scanning – up to 75% time savings without compromising image quality. The technology represents a significant advancement in the field, offering numerous benefits to patients, physicians, and medical facilities.
SubtlePET’s ability to expedite the imaging process reduces patient wait times and increases comfort, with the patient required to remain motionless under the camera for a shorter period of time, contributing to an overall more positive healthcare experience. Additionally, a shorter scan time for Illuccix will allow healthcare providers to further optimize workflows and resource utilization. Most importantly for facilities, SubtlePET seamlessly integrates into existing imaging center workflows, empowering healthcare providers to achieve faster PET imaging on any scanner, regardless of manufacturer or model. The technology can also extend scanner life through improved performance.
Also Read: PocketHealth Announces Dr. Seetharam Chadalavada as CMO
Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “Through this partnership, we are excited to incorporate an innovative AI product into the Illuccix value proposition for our customers and the patients they serve. We believe that the combination of Illuccix and SubtlePET will further strengthen Telix’s AI toolkit and also Illuccix’s reputation as the best-in-class PSMA-PET imaging agent for accuracy, reliability, quality, and operational excellence in the U.S. As Telix looks to our future with a multi-product portfolio, we look forward to growing our partnership with Subtle Medical to advance patient care and more efficient PET workflows across the disease spectrum.”
Josh Gurewitz, Chief Commercial Officer, Subtle Medical, commented, “We are pleased to commercially partner with Telix, a global leader in theranostics. This agreement represents a significant milestone for both companies, as we join forces to empower medical professionals and improve outcomes for patients with Subtle Medical’s platform and innovative AI product for PET imaging, starting with prostate cancer.”
The partnership with Telix, which covers North America and the European Union (EU, excluding France and French speaking Belgium), launches in the United States (U.S.) with Illuccix, with the aim to expand to other Telix PET-tracers, subject to regulatory approval.
SOURCE: GlobeNewswire